GROWTH HORMONE / PEPTIDE CARD

Sermorelin

A synthetic fragment of growth hormone-releasing hormone with historical clinical use and no current FDA-approved drug product.

PEPTIDE CARDSermorelin

Reviewed
August 7, 2026

Human evidence

2/5 · Historical human use

U.S. FDANot FDA approved

2026 WADAProhibited

Inspect 2 sources

On this page

WHAT THE EVIDENCE SAYS

Sermorelin evidence summary.

Sermorelin has a longer clinical history than many wellness-market peptides, but historical use is not the same as a current approved product or modern outcomes evidence.

Entity type
Peptide analogSource snapshot
August 7, 2026Record status
Sources attached

Do not overread this record

Claims about body composition, sleep, or anti-aging require their own clinical evidence.

01 / CLASSIFICATION

What is Sermorelin?

Entity typePeptide analog

Research categoryGrowth Hormone

Known namesSermorelin

Editorial unitOne molecule or defined product record

Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.

Class: Growth-hormone-axis peptides Goal: Growth Hormone Axis

02 / EVIDENCE

Sermorelin human and preclinical evidence.

HUMAN

2/5 · Historical human use

Human growth-hormone testing and treatment literature exists, but no current FDA-approved sermorelin product was identified.

PRECLINICAL

3/5 · Mechanism established

GHRH receptor activity is established; modern comparative outcomes evidence is limited.

The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.

03 / STATUS

Sermorelin FDA and sport status.

U.S. FDANo current FDA-approved drug product identified in the August 2026 source snapshot.

2026 WADAProhibited at all times under the 2026 WADA List (S2).

Commercial accessPeptideAgent does not route unapproved research substances to sellers.

Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.

04 / RESEARCH AREAS

What is Sermorelin being studied for?

01Growth hormone diagnostics

02Growth hormone deficiency

03GHRH physiology

05 / COMPARISONS

Compare Sermorelin.

Tesamorelin vs SermorelinCurrent approval and evidence context for two GHRH analogs.Ipamorelin vs SermorelinTwo unapproved growth-hormone-axis peptides with different mechanisms and evidence histories.CJC-1295 vs SermorelinA long-acting GHRH analog compared with a shorter historical GHRH fragment.

06 / LATEST & DEFINING SOURCES

Sermorelin primary and official sources.

FDA / 2026Drugs@FDA database

U.S. FDA

WADA / 20262026 Prohibited List

World Anti-Doping Agency

07 / QUESTIONS

Questions about Sermorelin.

Start with identity, research, human evidence, approval, sport status, and the limits of the current record.

EvidenceWhat is the evidence for Sermorelin?

Sermorelin has a longer clinical history than many wellness-market peptides, but historical use is not the same as a current approved product or modern outcomes evidence.

ResearchWhat is Sermorelin being studied for?

Current source-backed research areas include Growth hormone diagnostics, Growth hormone deficiency, GHRH physiology. These areas describe investigation, not established personal benefit.

FDA statusIs Sermorelin FDA approved?

Current U.S. status for Sermorelin: No current FDA-approved drug product identified in the August 2026 source snapshot.

Sport statusIs Sermorelin prohibited in sport?

Current sport-status snapshot for Sermorelin: Prohibited at all times under the 2026 WADA List (S2).

Evidence limitsWhat are the main evidence limits for Sermorelin?

Claims about body composition, sleep, or anti-aging require their own clinical evidence.